Nyxoah (NYXH)
(Delayed Data from NSDQ)
$9.76 USD
-0.17 (-1.71%)
Updated May 3, 2024 03:59 PM ET
After-Market: $9.76 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NYXH 9.76 -0.17(-1.71%)
Will NYXH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for NYXH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NYXH
Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates
Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates
NYXH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nextgen Healthcare (NXGN) Surpasses Q2 Earnings and Revenue Estimates
Nyxoah SA (NYXH) Reports Q2 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
Other News for NYXH
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Nyxoah (NYXH) and Zoetis (ZTS)
Nyxoah SA Welcomes New Chief Medical Officer
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Enlivex Therapeutics, Nyxoah SA, China SXT Pharmaceuticals among healthcare movers